| 23andMe, me, me All seven independent directors of the DNA testing company 23andMe resigned last week after its founder, Anne Wojcicki, failed to produce an “actionable” plan to take the company private. So what? It’s an astonishing motion of no-confidence in Wojcicki and her vision of bringing genetic testing to the masses. Since its inception in 2006, over 14 million people have used the services of 23andMe, spitting into test tubes in the hope of tracing their family trees. The upshot hasn’t always been happy. But horror stories (like finding you were switched with another baby at birth, or have been sleeping with a half-sibling) aren’t the reason 23andMe’s stock has plunged 99 per cent since it went public in 2021. That’s because of an unsustainable business model, a cavalier approach to privacy and regulation, and a headstrong founder who led in accordance with the Silicon Valley mantra of “move fast and break things”. Bay area Barbie. No one could accuse Wojcicki of lacking self-belief. Raised on the Stanford campus by academic parents, she went on to Yale and several hedge funds before diving into the sink-or-swim world of medical testing. In 2007 she married Sergey Brin and secured funding from Google, which he co-founded. Four years later 23andMe floated for $6 billion, getting free PR from celebrities attending “spit parties”. Wojcicki’s success followed her sisters’; Janet, who became a paediatrics professor, and Susan, the former CEO of Youtube who died last year. In March 2023, Mattel launched a set of Barbie dolls based on the Wojcicki sisters in celebration of International Women’s Day. At the time, 23andMe was going through its first round of layoffs. Going it alone. The problem with selling DNA tests is that customers only need to take them once. 23andMe’s plan to sell bespoke subscriptions foundered and its more recent forays into telehealth medicine and obesity drugs have yet to yield results. Fed up with the punishing life of a listed company, Wojcicki, who owns 49 per cent of 23andMe, hatched a plan to take it private. Board members including Roelof Botha, managing partner at Sequoia Capital, and Neal Mohan, the head of Youtube, were initially open to the plan. But Wojcicki’s proposal in late July to buy out at $0.40 a share failed to offer any premium for shareholders. Within two months the board resigned en-masse saying, “after months of work, we have yet to receive from you a fully financed, fully diligenced, actionable proposal.” Wojcicki is now the sole headshot on 23andMe’s directors’ webpage. In response to questions about her plans, a spokesperson for Wojcicki directed Tortoise to a memo she sent to employees in which she said she was surprised and disappointed by the resignations. Testing, testing. Some of 23andMe’s troubles stem from an insouciant approach to privacy. Last year the company was the victim of a devastating data breach which affected 7 million customers, some of whom were targeted on the basis of their ethnicity when sensitive genetic data was posted on forums on the dark web; took six months to identify and involved a fairly basic hacking technique called “credential stuffing”; and led to a class-action lawsuit which is expected to be settled for $30 million. Some lawyers involved in the suit aren’t satisfied with the proposed settlement and say it doesn’t go far enough in investigating who else has access to 23andMe’s data. The company says around 80 per cent of its customers opt in to let their information be used for genetic research and drug development. This has helped it secure data-sharing deals with GSK and others “We want to know if they’ve given data to other people. We want to know what permission they got to do that,” says Eli Wade-Scott at Edelson PC. He says Wojcicki’s take-private offer is an “indication that the CEO wants to pull this into a place where nobody can have that information anymore”. What’s more… There’s a risk that 23andMe’s data trove could “time-out” as scientists move to more expansive sequencing of the genome. One immediate option is acquisition: New York-based Nucleus Genomics says it’s considering making a public offer. Wojcicki might be wise to take the Valley approach and move fast. |
-
Archives
- December 2025
- November 2025
- October 2025
- September 2025
- August 2025
- July 2025
- June 2025
- May 2025
- April 2025
- March 2025
- February 2025
- January 2025
- December 2024
- November 2024
- October 2024
- September 2024
- August 2024
- July 2024
- June 2024
- May 2024
- April 2024
- March 2024
- February 2024
- January 2024
- December 2023
- November 2023
- October 2023
- September 2023
- August 2023
- July 2023
- June 2023
- May 2023
- April 2023
- March 2023
- February 2023
- January 2023
- December 2022
- November 2022
- October 2022
- September 2022
- August 2022
- July 2022
- June 2022
- May 2022
- April 2022
- March 2022
- February 2022
- January 2022
- September 2021
- August 2021
- July 2021
- June 2021
- May 2021
- April 2021
- February 2021
- January 2021
- December 2020
- November 2020
- October 2020
- September 2020
- August 2020
- July 2020
- June 2020
- May 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- March 2015
- January 2015
-
Meta